Sinotherapeutics Inc. (SHA:688247)
China · Delayed Price · Currency is CNY 7.95
-0.27 (-3.28%)
At close: Nov 13, 2026
Sinotherapeutics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 397.16 | 446.05 | 511.08 | 299.41 | 246.69 | 314.38 |
Other Revenue | 0.52 | 0.52 | 0.54 | 0.46 | 0.87 | 1.09 |
| 397.68 | 446.57 | 511.62 | 299.87 | 247.56 | 315.47 | |
Revenue Growth | -17.23% | -12.72% | 70.61% | 21.13% | -21.53% | -1.16% |
Cost of Revenue | 257.18 | 285.98 | 246.11 | 133.5 | 68.44 | 70.44 |
Gross Profit | 140.5 | 160.59 | 265.51 | 166.37 | 179.12 | 245.03 |
Selling, General & Admin | 49.76 | 47 | 55.25 | 43.93 | 43.9 | 45.71 |
Research & Development | 85.19 | 74.94 | 84.92 | 74.01 | 76.02 | 103.63 |
Other Operating Expenses | 5.65 | 2.69 | 2.19 | 3.03 | -0.63 | 0.77 |
Operating Expenses | 143.47 | 125.97 | 146.02 | 122.07 | 120.91 | 149.94 |
Operating Income | -2.97 | 34.62 | 119.48 | 44.3 | 58.21 | 95.1 |
Interest Expense | -0 | -0 | -0 | -0.04 | -0.21 | -0.23 |
Interest & Investment Income | 16.77 | 15.23 | 16.38 | 17.45 | 25.02 | 5.66 |
Currency Exchange Gain (Loss) | -3.69 | -3.69 | 2.07 | 1.26 | 5.52 | -4 |
Other Non Operating Income (Expenses) | 2.57 | -0.09 | -0.07 | -0.06 | -0.05 | 0.43 |
EBT Excluding Unusual Items | 12.69 | 46.06 | 137.86 | 62.91 | 88.48 | 96.95 |
Impairment of Goodwill | -2.16 | -2.16 | - | - | - | - |
Gain (Loss) on Sale of Investments | 1.34 | 1.34 | - | - | - | 0.46 |
Gain (Loss) on Sale of Assets | -0.34 | -0.36 | -0.59 | -0.11 | 0.12 | -0.02 |
Asset Writedown | -1.66 | -0.24 | -0.92 | -1.62 | -0.85 | -0.1 |
Other Unusual Items | 10.49 | 8.7 | 5.74 | 4.8 | 9.73 | 51.72 |
Pretax Income | 20.35 | 53.34 | 142.08 | 65.99 | 97.48 | 149.01 |
Income Tax Expense | 2.25 | 5.85 | 14.38 | 4.92 | 4.54 | 14.1 |
Net Income | 18.1 | 47.48 | 127.7 | 61.07 | 92.93 | 134.92 |
Net Income to Common | 18.1 | 47.48 | 127.7 | 61.07 | 92.93 | 134.92 |
Net Income Growth | -81.64% | -62.82% | 109.09% | -34.28% | -31.12% | 9.42% |
Shares Outstanding (Basic) | 411 | 432 | 456 | 470 | 422 | 409 |
Shares Outstanding (Diluted) | 411 | 432 | 456 | 470 | 422 | 409 |
Shares Change | -11.65% | -5.35% | -2.92% | 11.22% | 3.32% | 0.21% |
EPS (Basic) | 0.04 | 0.11 | 0.28 | 0.13 | 0.22 | 0.33 |
EPS (Diluted) | 0.04 | 0.11 | 0.28 | 0.13 | 0.22 | 0.33 |
EPS Growth | -79.22% | -60.71% | 115.39% | -40.91% | -33.33% | 10.00% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 79.83 | 53.77 | 35.3 | -26 | -103.15 | 129.77 |
Free Cash Flow Per Share | 0.19 | 0.13 | 0.08 | -0.06 | -0.24 | 0.32 |
Dividend Per Share | 0.010 | 0.035 | 0.062 | 0.041 | 0.062 | - |
Dividend Growth | -83.87% | -43.55% | 51.22% | -33.87% | - | - |
Gross Margin | 35.33% | 35.96% | 51.90% | 55.48% | 72.35% | 77.67% |
Operating Margin | -0.75% | 7.75% | 23.35% | 14.77% | 23.51% | 30.14% |
Profit Margin | 4.55% | 10.63% | 24.96% | 20.37% | 37.54% | 42.77% |
Free Cash Flow Margin | 20.07% | 12.04% | 6.90% | -8.67% | -41.67% | 41.13% |
EBITDA | 22.9 | 60.01 | 144.26 | 67.38 | 83.75 | 121.21 |
EBITDA Margin | 5.76% | 13.44% | 28.20% | 22.47% | 33.83% | 38.42% |
D&A For EBITDA | 25.87 | 25.4 | 24.77 | 23.08 | 25.55 | 26.12 |
EBIT | -2.97 | 34.62 | 119.48 | 44.3 | 58.21 | 95.1 |
EBIT Margin | -0.75% | 7.75% | 23.35% | 14.77% | 23.51% | 30.14% |
Effective Tax Rate | 11.07% | 10.97% | 10.12% | 7.45% | 4.66% | 9.46% |
Revenue as Reported | 115.1 | 446.57 | 511.62 | 299.87 | 247.56 | 315.47 |
Advertising Expenses | - | 1.51 | 0.77 | 0.42 | 0.69 | - |